A double-blind, placebo-controlled, randomised, multi-centre, 3-way cross-over, single-dose phase II study to investigate the local and systemic effects of inhaled AZD8683 in patients with chronic obstructive pulmonary disease (COPD)
The purpose of this study is to investigate effects of inhaled AZD8683 compared to placebo in COPD patients.